ArticleXenotransplantation
Is There an Ethical Dilemma in Xenotransplantation?
Article in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Xenotransplantation Literature Update: January-June 2026.XenotransplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As clinical trials in xenotransplantation commence, the question of whether participants may withdraw from research is being intensely debated. Some authors argue that xenotransplant recipients should be subject to lifelong monitoring because of the potential risk of zoonotic or xenozoonotic infections affecting third parties. Others maintain that the right to withdraw from research participation is a fundamental principle of medical ethics that must not be compromised. To clarify this tension, historical precedents have been examined, and the applicability of so-called Ulysses contracts to xenotransplantation has been critically assessed. The practical answer is more straightforward than the theoretical debate suggests: xenotransplant recipients, like allotransplant recipients, require continuous medical supervision. Lifelong immunosuppression and regular follow-up are essential to preserve transplant function and, ultimately, the patient's life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.